Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

38.02
+0.51001.36%
Post-market: 38.690.6700+1.76%17:50 EDT
Volume:1.45M
Turnover:56.40M
Market Cap:2.66B
PE:-12.70
High:40.60
Open:38.13
Low:37.47
Close:37.51
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.73
T/O Rate:3.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.61
PE(LYR):-10.90

Loading ...

Pharvaris Director Robert Glassman Disposes of Common Shares Worth $300,396

Reuters
·
5 hours ago

BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says

MT Newswires Live
·
Sep 10

Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (XERS) and Pharvaris (PHVS)

TIPRANKS
·
Sep 10

Pharvaris Price Target Raised to $65.00/Share from $50.00 by Leerink Partners

Dow Jones
·
Sep 10

Sweden's Biovica Q1 Sales Rise on Pharma Services Growth

Reuters
·
Sep 09

Pharvaris President Lu Peng Disposes of USD 610,134 Common Shares

Reuters
·
Sep 09

Pharvaris (PHVS) Gets a Buy from Leerink Partners

TIPRANKS
·
Sep 09

Pharvaris price target raised to $65 from $52 at Jones

TIPRANKS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pharvaris (PHVS) and Zimmer Biomet Holdings (ZBH)

TIPRANKS
·
Sep 09

Pharvaris N.v. : RBC Raises Target Price to $62 from $52

THOMSON REUTERS
·
Sep 09

Pharvaris: Kbc Securities Raises Target Price to $49 from $39; Rating Buy

THOMSON REUTERS
·
Sep 09

Pharvaris price target raised to $75 from $50 at Oppenheimer

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Top Midday Gainers

MT Newswires Live
·
Sep 09

Pharvaris Shares Rise on Positive Results for Hereditary Angioedema Trial

Dow Jones
·
Sep 08

Wedbush Adjusts Pharvaris Price Target to $50 From $42, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Pharvaris rises 16.7%

TIPRANKS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Shares of Pharvaris up 14% After Co's Genetic Disorder Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Sep 08

Pharvaris Price Target Maintained with a $42.00/Share by Wedbush

Dow Jones
·
Sep 08